Magle Chemoswed Holding AB - ESG Rating & Company Profile powered by AI
The ESG assessment for Magle Chemoswed Holding AB indicates the company's reporting of the United Nations SDGs. If you work at Magle Chemoswed Holding AB and you wish to use your ESG aseessment, please get in touch. The assessment of Magle Chemoswed Holding AB was prepared by All Street Sevva using cutting edge machine learning.
Magle Chemoswed Holding AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 4.0, social score of 2.7 and governance score of 5.3.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
989 | Spectrum Pharmaceuticals Inc | 4.1 | High |
989 | Tricida Inc | 4.1 | High |
1004 | Magle Chemoswed Holding AB | 4.0 | High |
1004 | Can B Corp | 4.0 | High |
1004 | CLS Holdings USA Inc | 4.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Magle Chemoswed Holding AB have an accelerator or VC vehicle to help deliver innovation?
Does Magle Chemoswed Holding AB disclose current and historical energy intensity?
Does Magle Chemoswed Holding AB report the average age of the workforce?
Does Magle Chemoswed Holding AB reference operational or capital allocation in relation to climate change?
Does Magle Chemoswed Holding AB disclose its ethnicity pay gap?
Does Magle Chemoswed Holding AB disclose cybersecurity risks?
Does Magle Chemoswed Holding AB offer flexible work?
Does Magle Chemoswed Holding AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Magle Chemoswed Holding AB disclose the number of employees in R&D functions?
Does Magle Chemoswed Holding AB conduct supply chain audits?
Does Magle Chemoswed Holding AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Magle Chemoswed Holding AB conduct 360 degree staff reviews?
Does Magle Chemoswed Holding AB disclose the individual responsible for D&I?
Does Magle Chemoswed Holding AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Magle Chemoswed Holding AB disclose current and / or historical scope 2 emissions?
Does Magle Chemoswed Holding AB disclose water use targets?
Does Magle Chemoswed Holding AB have careers partnerships with academic institutions?
Did Magle Chemoswed Holding AB have a product recall in the last two years?
Does Magle Chemoswed Holding AB disclose incidents of discrimination?
Does Magle Chemoswed Holding AB allow for Work Councils/Collective Agreements to be formed?
Has Magle Chemoswed Holding AB issued a profit warning in the past 24 months?
Does Magle Chemoswed Holding AB disclose parental leave metrics?
Does Magle Chemoswed Holding AB disclose climate scenario or pathway analysis?
Does Magle Chemoswed Holding AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Magle Chemoswed Holding AB disclose the pay ratio of women to men?
Does Magle Chemoswed Holding AB support suppliers with sustainability related research and development?
Does Magle Chemoswed Holding AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Magle Chemoswed Holding AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Magle Chemoswed Holding AB involved in embryonic stem cell research?
Does Magle Chemoswed Holding AB disclose GHG and Air Emissions intensity?
Does Magle Chemoswed Holding AB disclose its waste policy?
Does Magle Chemoswed Holding AB report according to TCFD requirements?
Does Magle Chemoswed Holding AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Magle Chemoswed Holding AB disclose energy use targets?
Does Magle Chemoswed Holding AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Magle Chemoswed Holding AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Magle Chemoswed Holding AB
These potential risks are based on the size, segment and geographies of the company.
Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.